Jump Financial LLC bought a new position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 81,855 shares of the biopharmaceutical company's stock, valued at approximately $2,088,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Franklin Resources Inc. boosted its position in shares of Royalty Pharma by 5.0% during the 3rd quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company's stock worth $40,705,000 after acquiring an additional 70,130 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Royalty Pharma by 4.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company's stock worth $79,888,000 after acquiring an additional 130,025 shares in the last quarter. Pallas Capital Advisors LLC acquired a new stake in shares of Royalty Pharma during the 4th quarter worth approximately $2,355,000. Jupiter Asset Management Ltd. bought a new stake in Royalty Pharma during the 4th quarter worth $4,950,000. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Royalty Pharma by 303.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 539,995 shares of the biopharmaceutical company's stock valued at $13,926,000 after buying an additional 406,123 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.
Analyst Upgrades and Downgrades
Separately, Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $42.50.
Read Our Latest Stock Analysis on Royalty Pharma
Royalty Pharma Stock Performance
Royalty Pharma stock traded up $0.34 during mid-day trading on Thursday, reaching $32.03. 856,312 shares of the company's stock were exchanged, compared to its average volume of 3,242,425. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. The business's fifty day simple moving average is $32.54 and its 200 day simple moving average is $29.36. The firm has a market capitalization of $18.47 billion, a PE ratio of 22.09, a P/E/G ratio of 2.31 and a beta of 0.50. Royalty Pharma plc has a one year low of $24.05 and a one year high of $34.20.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, sell-side analysts expect that Royalty Pharma plc will post 4.49 earnings per share for the current year.
Royalty Pharma Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 2.75%. The ex-dividend date is Friday, May 16th. Royalty Pharma's payout ratio is 60.69%.
About Royalty Pharma
(
Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Featured Stories
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
